Simms, Kefi has a 1.1mn oz resource here on the proposed mine, roughly comparable to that of Condor. Grades aren't great overall, at 2.1g/t but economic, nevertheless. Which of the two projects offers the greater upside on development, to the 3mn+ oz level over a realistic time frame? Cnr is valued at twice Kefi, to bear in mind.
What disappoints me most about ANS is their sheer arrogance in keeping both Kefi and their own EG in the dark about their financial contribution plans right up until their exclusivity period ended. And Kefi is still talking in today's RNS about including them in a wider consortium for the project finance. Unbelievable.
There is much more to AVCT than a rapid POC test for covid19. Get the Affimer platform accepted through a clinical trial and the value of the IP will be multiples of where it is today, through "proof of concept". It is not a one trick pony.
Trapper, I understand where you're coming from. You think "significant" means a significant monetary amount of contract. If that were the case, I would agree with you, that 2 personnel for 5 months each, is not going to light this share much. So I think PYC in this case means a significant new customer, i.e. a large pharma, that will both solidify PYC's reputation in their field, as well as lead potentially to much larger monetary business with them over the course of time.
RE: Wow the troll is in overdrive30 Jun 2020 15:13
I think Mr Market is saying, "We like the new team at ADME, but we have little idea just exactly how they can pull off a premium placing to avoid excessive dilution with a MC of just £2mn, even with Trafigura's backing. This is AIM after all, where placings come at discounts, often big ones."
Good morning BBN. Yes, GDR is in the zone for big regulatory news. The issue for management here is their business/selling acumen. They don't exactly have a stellar record of sales successes and mega distribution deals that are already pulling in £mns of revenue. Will the HCV WHO-approved test go the same way? A great product but so far no public declaration of any sales, or sales orders in the works. At least NCYT had sales orders pending regulatory approvals. They appear to be a mean sales operation, even if their product is not on the same level of technical quality as the GeneDrive96.